Hims & Hers (NYSE: HIMS) has seen incredibly high growth, but the market is skeptical that will continue. In this video, ...

That’s how long it’s been since Tom Izzo last hoisted a national championship trophy and apparently, the last time he’s felt anything.

“RKLX and HIMZ offer compelling opportunities for investors seeking amplified exposure to Rocket Lab and Hims & Hers, two companies driving innovation in their respective industries,” said ...

HIMZ, the Defiance Daily Target 2X Long HIMS ETF, seeks daily investment results that correspond to twice (200%) the daily return of Hims & Hers, a company pioneering telehealth and direct-to ...

These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account. “RKLX and HIMZ offer compelling opportunities for investors seeking ...

These ETFs offer traders a way to seek enhanced returns on Rocket Lab and Hims & Hers without requiring a margin account.

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company’s subscriber base reached 2.2 million ...